Clopidogrel: where the agencies disagree
This page collects every recorded health technology assessment decision for one molecule across the agencies in our archive, and compares them. The comparison is the point: each agency publishes its own verdict, none publishes how that verdict sits against the others.
What the record shows
PBAC (Australia), PHARMAC (New Zealand) and SMC (Scotland) recommended or restricted clopidogrel, while AWMSG (Wales) did not recommend it.
PHARMAC (New Zealand) has been easier on clopidogrel than on its own caseload: it refused 0 of 6 decisive submissions here (0%), against a base rate of 29% across everything it has assessed.
The file has been open for more than a decade: 21.8 years separate the first record, 8 Mar 2004 at SMC (Scotland), from the most recent, 17 Dec 2025 at HAS (France).
No assessment is on file from TLV (Sweden), CIPM (Spain) and G-BA (Germany), each among the eight highest-volume agencies here.
5 distinct indication wordings are recorded for clopidogrel by the agencies that label one in English (AWMSG, PBAC and SMC).
1 of these 16 records carries a year of decision but no day, so any interval quoted here is approximate to within a year.
SMC (Scotland) was first to assess clopidogrel, on 8 Mar 2004; PBAC (Australia) did not open a file until 2021 — an unusually long tail of 17.3 years between the earliest and latest system to look at it.
The record arrives in waves: 3 separate years each carry two or more decisions, spread across 10 years in total.
3 of the 5 agencies here assessed clopidogrel more than once, PHARMAC (New Zealand) most often at 6 entries — repeat review is the norm for this molecule rather than the exception.
Coverage is narrow: only 5 of the 18 agencies here have assessed clopidogrel.
The full ledger for clopidogrel reads 8 recommended, 3 not recommended, 3 restricted and 1 not assessed, with 1 in other categories.
Decisions on file
| Agency | Date | Indication as recorded | Outcome | Source |
|---|---|---|---|---|
| PBAC (Australia) | 2021 | Antithrombotic | Recommended | source |
| AWMSG (Wales) | 24 Jun 2021 | In combination with aspirin in adult patients with moderate to high-risk Transient Ischaemic Attack (TIA) (ABCD2 score ≥… | not endorsed (non-submission) | source |
| PHARMAC (New Zealand) | 13 Aug 2009 | Widening access to 12 months (from 3 months) for Acute Coronary Syndrome (ACS) | PTAC advice: Low · decision reached | source |
| HAS (France) | 18 Apr 2007 | Indication extension | ASMR III | source |
| SMC (Scotland) | 8 Mar 2004 | Prevention of atherothrombotic events in acute coronary syndrome | accepted (restricted) | source |
11 further decisions for clopidogrel, across 3 agencies, are not shown here. They include the most recent record on file, 17 Dec 2025 from HAS (France); its outcome is in the subscriber dataset. They link to 9 further source documents.
Related molecules
- rivaroxaban — same ATC class B01A — Antithrombotics
- apixaban — same ATC class B01A — Antithrombotics
- enoxaparin — same ATC class B01A — Antithrombotics
- dabigatran — same ATC class B01A — Antithrombotics
- fondaparinux — same ATC class B01A — Antithrombotics
- ticagrelor — same ATC class B01A — Antithrombotics
Coverage: 16 decisions for clopidogrel from 5 agencies, 2004 to 2025. Data to 7 Sep 2026. ATC class B01A — Antithrombotics. How this page is produced. Compiled by Altima Partners; queries: sales@altimapartners.co.uk.